New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
06:06 EDTCYTRCytRx's aldoxorubicin for sarcomashows positive Phase 2b clinical trial results
CytRx's oral presentation titled “Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas,” was featured in The Lancet Oncology in its July issue. The updated results from CytRx’s ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable STS demonstrated that aldoxorubicin significantly increases progression-free survival, PFS at 6 months, overall response rate and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. The data trended in favor of aldoxorubicin for all of the major subtypes of STS. The company is on track to report the full overall survival results from this trial prior to year-end.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:09 EDTCYTRCytRx announces positive data from Phase 1b/2 study of Aldoxorubicin
Subscribe for More Information
October 17, 2014
09:17 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
06:15 EDTCYTRCytRx aldoxorubicin trial not yet reached enough survival events to report OS
CytRx announced that data regarding the company's Phase 2b global clinical trial of aldoxorubicin for the treatment of first-line soft tissue sarcoma, or STS, will be presented in a moderated paper presentation at the 2014 Connective Tissue Oncology Society Annual Meeting which is being held October 15-18, 2014, in Berlin, Germany. Due to the longer than expected survival of patients in the clinical trial, there have not been a sufficient number of survival events to enable the company to report data on overall survival, or OS, a secondary endpoint of the study.
October 13, 2014
06:03 EDTCYTRCytRx commenced operations at new discovery laboratory
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use